Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Theravance Biopharma Inc shares valued at $113,870 were sold by Farnum Rhonda on Jul 14 ’25. At $11.39 per share, Farnum Rhonda sold 10,000 shares. The insider’s holdings dropped to 326,918 shares worth approximately $4.59 million following the completion of this transaction.
Also, RHONDA FARNUM purchased 10,000 shares, netting a total of over 113,869 in proceeds.
Before that, Farnum Rhonda had sold 24,000 shares from its account. In a trade valued at $264,000, the SVP, COMM & MEDICAL AFFAIRS traded Theravance Biopharma Inc shares for $11.00 each. Upon closing the transaction, the insider’s holdings decreased to 24,000 shares, worth approximately $4.73 million.
As published in a research note from Leerink Partners on August 06, 2024, Theravance Biopharma Inc [TBPH] has been rated down from an Outperform to a Market perform and the price target has been revised to $10 from $15. Analysts at BTIG Research started covering the stock with ‘”a Buy”‘ outlook in a report released in mid April. As of January 08, 2024, Evercore ISI has decreased its “an Outperform” rating to a “an In-line” for TBPH. Earlier on May 23, 2022, SVB Leerink initiated its rating. Their recommendation was “an Outperform” for TBPH stock.
Analyzing TBPH Stock Performance
On last trading session, Theravance Biopharma Inc [NASDAQ: TBPH] rose 2.29% to $14.05. The stock’s lowest price that day was $13.66, but it reached a high of $14.09 in the same session. During the last five days, there has been a surge of approximately 1.81%. Over the course of the year, Theravance Biopharma Inc shares have jumped approximately 70.30%. Shares of the company reached a 52-week high of $14.55 on 09/02/25 and a 52-week low of $7.90 on 04/07/25.
Support And Resistance Levels for Theravance Biopharma Inc (TBPH)
According to the 24-hour chart, there is a support level at 13.78, which, if violated, would cause prices to drop to 13.50. In the upper region, resistance lies at 14.21. The next price resistance is at 14.36. RSI (Relative Strength Index) is 74.55 on the 14-day chart, showing overbought technical sentiment.
Is Theravance Biopharma Inc subject to short interest?
Stocks of Theravance Biopharma Inc saw a sharp steep in short interest on 2025-08-15 dropping by -0.39 million shares to 3.56 million. Data from Yahoo Finance shows that the short interest on 2025-07-15 was 3.95 million shares. A decline of -10.86% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 12.47 of the overall float, the days-to-cover ratio (short ratio) decline to 12.47.
Which companies own the most shares of Theravance Biopharma Inc (TBPH)?
In terms of Theravance Biopharma Inc share price expectations, FactSet research, analysts set an average price target of 15 in the next 12 months, up nearly 9.25% from the previous closing price of $13.73. Analysts anticipate Theravance Biopharma Inc stock to reach 21 by 2025, with the lowest price target being 10. In spite of this, 3 analysts ranked Theravance Biopharma Inc stock as Buy at the end of 2025. On November 05, 2021, JP Morgan assigned a price target of “a Neutral” to the stock and upgraded coverage with a $12.
